{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:31:58Z","timestamp":1773819118168,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bcp.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T12:48:29Z","timestamp":1531918109000},"page":"298-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Small molecules bind human mTOR protein and inhibit mTORC1 specifically"],"prefix":"10.1016","volume":"155","author":[{"given":"Sonia A.","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Tomilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino A.","family":"Cortopassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.07.013_b0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ceb.2014.12.001","article-title":"mTOR signaling in cellular and organismal energetics","volume":"33","author":"Albert","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"issue":"10","key":"10.1016\/j.bcp.2018.07.013_b0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiotics"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.013_b0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1254\/jjp.71.89","article-title":"Immunosuppression in organ transplantation","volume":"71","author":"Oka","year":"1996","journal-title":"Jpn. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.013_b0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4161\/cbt.5.9.3175","article-title":"Therapeutic targets: MTOR and related pathways","volume":"5","author":"Dancey","year":"2006","journal-title":"Cancer Biol. Therapy"},{"issue":"6165","key":"10.1016\/j.bcp.2018.07.013_b0025","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1244360","article-title":"mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome","volume":"342","author":"Johnson","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.013_b0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","article-title":"Dysregulation of mTOR signaling in fragile X syndrome","volume":"30","author":"Sharma","year":"2010","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.013_b0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.013_b0040","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/cam4.742","article-title":"The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors","volume":"5","author":"Phan","year":"2016","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.013_b0045","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/cncr.29927","article-title":"A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer","volume":"122","author":"Chow","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2018.07.013_b0050","first-page":"5","article-title":"mTOR inhibitors in cancer therapy","author":"Xie","year":"2016","journal-title":"F1000Research"},{"issue":"19","key":"10.1016\/j.bcp.2018.07.013_b0055","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/1873-3468.12711","article-title":"mTORC1 and mTORC2 as regulators of cell metabolism in immunity","volume":"591","author":"Linke","year":"2017","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.013_b0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/ncb2763","article-title":"Signal integration by mTORC1 coordinates nutrient input with biosynthetic output","volume":"15","author":"Dibble","year":"2013","journal-title":"Nature Cell Biol."},{"issue":"18","key":"10.1016\/j.bcp.2018.07.013_b0065","doi-asserted-by":"crossref","first-page":"15461","DOI":"10.1074\/jbc.C200665200","article-title":"The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif","volume":"278","author":"Nojima","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.bcp.2018.07.013_b0070","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"issue":"5712","key":"10.1016\/j.bcp.2018.07.013_b0075","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.013_b0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/aps.2015.68","article-title":"Toward rapamycin analog (rapalog)-based precision cancer therapy","volume":"36","author":"Meng","year":"2015","journal-title":"Acta Pharmacol. Sinica"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.013_b0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjms.2016.08.014","article-title":"Targeting the mammalian target of rapamycin in lung cancer","volume":"352","author":"Vicary","year":"2016","journal-title":"Am. J. Med. Sci."},{"issue":"20","key":"10.1016\/j.bcp.2018.07.013_b0090","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2174\/092986711796391651","article-title":"ATP-competitive inhibitors of mTOR: an update","volume":"18","author":"Schenone","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2018.07.013_b0095","unstructured":"C. Di Malta, D. Siciliano, A. Calcagni, J. Monfregola, S. Punzi, Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth, 2017, 356(6343), 1188\u20131192."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.013_b0100","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1074\/jbc.M113.526335","article-title":"Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling","volume":"289","author":"Chen","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.013_b0105","article-title":"A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice","author":"Morisot","year":"2017","journal-title":"Addict. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.013_b0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.bcp.2018.07.013_b0115","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1073\/pnas.0502857102","article-title":"The coordinate regulation of the p53 and mTOR pathways in cells","volume":"102","author":"Feng","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.bcp.2018.07.013_b0120","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1073\/pnas.92.11.4947","article-title":"Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue","volume":"92","author":"Chen","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"13","key":"10.1016\/j.bcp.2018.07.013_b0125","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through and IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.013_b0130","first-page":"835","article-title":"In vitro efficacy of cinnarizine against lymphoma and multiple myeloma","volume":"35","author":"Schmeel","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.013_b0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000226436","article-title":"In vitro and in vivo enhancement of vincristine antitumor activity on B16 melanoma cells by calcium antagonist flunarizine","volume":"44","author":"Bellelli","year":"1987","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.bcp.2018.07.013_b0140","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.1995.230","article-title":"Flunarizine enhancement of melphalan activity against drug-sensitive\/resistant rhabdomyosarcoma","volume":"71","author":"Castellino","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2018.07.013_b0145","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/bjc.1988.301","article-title":"Cinnarizine and flunarizine as radiation sensitisers in two murine tumours","volume":"58","author":"Wood","year":"1988","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.013_b0150","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1517\/13543784.17.11.1717","article-title":"mTOR inhibitors in the treatment of cancer","volume":"17","author":"Fasolo","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.013_b0155","first-page":"1369","article-title":"Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells","volume":"35","author":"Schmeel","year":"2015","journal-title":"Anticancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T09:17:55Z","timestamp":1576833475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218302818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":31,"alternative-id":["S0006295218302818"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.013","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecules bind human mTOR protein and inhibit mTORC1 specifically","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}